Eloxx Pharmaceuticals, Inc. (ELOX)
$13.03-4.89%Close
Snapshot
- 1 week
- -5.2%-3.2% vs SPY
- 1 month
- -26.1%-27.6% vs SPY
- Market cap
- $98.7M
- P/E
- negindustry 14.4
- P/B
- 1.9
- EV/EBITDA
- 2.1
- FCF yield
- -22.9%
- Short % float
- 0.7%
- Days to cover
- 2.4
- Short change
- +18.2%
- Consensus
- Buy9 buy · 3 hold · 0 sell
- Price target
- $37.67+189.1% upside
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Eloxx Pharmaceuticals, Inc. (ELOX). Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nep…
SEC filingsCIK 1035354
Profile
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUS
CEOSumit Aggarwal
IPOJun 9
Employees10
Shares outstanding7.6M
Float7.4M
Free float97.1%
Websiteeloxxpharma.com
Key executives
- Sumit AggarwalPresident, Chief Executive Officer & DirectorUSD 956K
- Daniel E. GeffkenInterim Chief Financial OfficerUSD 450K
- Roger ClarkVP & Head of Discovery Sciences
- Teji SinghVP & Head of Clinical Development
- John WoolfordVP & Head of Corporate Development
- Ali HaririChief Medical Officer
Fundamentals
SCORES & PROFILE
FUND, Value, Growth and GARP scores and the archetype
ROIC-25.5%
REV YoY-
ROE-42.5%
EPS YoY-
ROA-13.0%
GROSS0
OP0
NET0
VALUATION
P/E TTM-8.57
P/E FWD-
SECTOR PE20.69
INDUSTRY PE14.42
P/B1.91
P/FCF-
EV/EBITDA2.10
EV/EBIT-
FCF YIELD-22.87%
TRUE FCF YLD-23.40%
PEG-
Risk
INT COV-222.8×
D/E-
ALTMAN Z-4.93
CURR RATIO3.74
ND/EBITDA-
INTEREST COVERAGE < 1.5X (-222.84X)
